Key facts
- Steven Quay, a proponent of the lab-leak theory for COVID-19's origin, is in the final stages of vetting for the director role at the National Institute of Allergy and Infectious Diseases (NIAID).
- The position, previously held by Anthony Fauci, oversees $6.5 billion in health research funding.
- Quay, a physician and pathologist, has authored books arguing the virus originated from a Chinese lab and has alleged a cover-up by U.S. scientists.
- Health Secretary Robert F. Kennedy Jr. selected Quay, who was not advanced by NIH staff during the initial application review.
- The move comes amid ongoing partisan debate over COVID-19's origins and Fauci's role, with some U.S. agencies now leaning toward the lab-leak theory.
Steven Quay, a pharmaceutical executive and vocal proponent of the theory that COVID-19 originated from a Chinese lab, is reportedly in the final stages of vetting to become the next director of the National Institute of Allergy and Infectious Diseases (NIAID). The position, which was held by Anthony Fauci for decades, controls significant health research funding and has been vacant since last year.
Quay has authored books and testified before Congress, asserting that the virus originated from a lab and alleging a cover-up by U.S. scientists. His selection by Health Secretary Robert F. Kennedy Jr. signals a potential shift in the agency's direction, aligning with a growing number of U.S. agencies that now lean toward the lab-leak hypothesis.
This development occurs amidst heightened political scrutiny of Fauci and the pandemic's origins. Republicans have accused Fauci of funding research that may have contributed to the virus's creation, while Fauci has invoked his Fifth Amendment right against self-incrimination. The debate over the virus's origin remains contentious, with the World Health Organization favoring a natural zoonotic spillover, though some U.S. intelligence agencies and public health figures now find the lab-leak theory more plausible.
Quay's background as a physician and pathologist, and his experience as a founder of drug companies like Atossa Therapeutics, would mark a departure from previous NIAID directors who typically came from academia or the National Institutes of Health. His appointment is also supported by conservative advocacy groups focused on ending taxpayer-funded animal experiments. Quay has proposed reforms for high-risk research, including third-party review panels and better containment efforts.